期刊文献+

参附注射液联合西药治疗急性左心衰大鼠NT-proBNP变化的实验研究 被引量:12

The observation of NT-proBNP in acute left ventricular failure rats treated with Shenfu injection and medicine
原文传递
导出
摘要 目的:探索中药参附注射液治疗急性左心衰大鼠疗效对心力衰竭(心衰)指标NT-proBNP的影响。方法:采用急性左心衰大鼠模型,观察单用西药和参附注射液联合西药治疗前后15min、30min、60min和24h小时大鼠NT-proBNP、左室收缩末期压(LVESP)、左室内压最大上升速率(dp/dtmax)的变化。结果:参附注射液联合西药治疗急性左心衰大鼠前后30minNT-proBNP的变化具有统计学意义,联合治疗组优于单纯参附注射液组或单纯西药治疗组。结论:参附注射液对心肌细胞有正性肌力作用,NT-proBNP作为临床中药疗效观察的敏感指标应广泛应用于急性心衰治疗。 Objective:To explore the efficacy of NT-proBNP of acute left ventricular failure rats with the treat- ment of Chinese medicine Shenfu injection. Method:The group of rat model in acute left heart failure, observed the treatment indicators (NT-proBNP, LVESP, dp/dtmax) in sham operation group ,separate Chinese medicine, sep- arate Western medicine and combined group in 15 minutes, 30 minutes, 60 minutes and 24 hours. Result: NT- proBNP is statistically significant in the group of 30 minutes treatment of Shenfu injection combined Western medi- cine rates with acute left ventrieular failures. The efficacy of eomhination therapy group is better than the separate Shenfu injection group and separate Western medicine group. Conclusion: The Shenfu injection has positive ino- tropic effect on myocardial cells. NT-proBNP as a sensitive indicator of the observation in the clinical traditional Chinese medicines and widely used in the observation the efficacy of acute heart failure.
出处 《临床急诊杂志》 CAS 2012年第4期276-278,共3页 Journal of Clinical Emergency
基金 武汉市卫生局科研资助项目(No:WZ11C03)
关键词 参附注射液 急性左心衰 NT-PROBNP Chinese medicine Shenfu injection acute left heart failure NT-proBNP
  • 相关文献

参考文献9

  • 1中华人民共和国卫生部.中药新药临床研究指导原则[M].南京:南京医科大学出版社,1993:250.
  • 2郑世营,张晓膺,李虹,狄冬梅,葛锦峰.参附注射液对心肌细胞缺氧及缺氧/复氧时Fas/FasL表达的影响[J].中国急救医学,2005,25(12):893-895. 被引量:14
  • 3OUANES I, J ALLOUI. F,AYED S, et al. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction[J]. J Respirology,2012, 2:305-322.
  • 4WONG G C, AYAS N T. Clinical approaches to the diagnosis of acute heart failure[J]. J Curt Opin Cardi- ol,2007,22 : 207- 213.
  • 5DE DENUS S, LAVOIE J, DUCHARME A , et al. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraetion[J]. J Can J Cardiol, 2012,28:62 - 68.
  • 6AMODIO G, ANTONELLI G, DI SERIO F. Cardiac biomarkers in acute coronary syndromes:a review[J]. J Curr Vasc Pharmacol, 2010,8 : 388- 393.
  • 7TAMURA N,OGAWA Y,CHUSHO H. Cardiac fi- brosis in mice lacking brain natriuretic peptide[J]. J Proc Natl Acad Sci USA,2000,97:4239-4244.
  • 8SELVAIS P L,DONCKIER J E,ROBERT A. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventrieular dysfunc- tion and coronary artery disease on cardiac hormonal activation[J]. Eur J Clin Invest, 1998,28 : 636 - 642.
  • 9NACB Writing Group,WU A H,JAFFE A S,et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proPrtype natriuretic peptide for etiologies other than acute coro- nary syndromes and heart failure[J]. J Clin Chem, 2007,53 : 2086- 2096.

二级参考文献6

共引文献23

同被引文献91

引证文献12

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部